Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection
| Autor: | Sang Hoon Ahn, Taegon Hong, Min Soo Park, Jun Yong Park, Hye Won Lee |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
HBsAg
Hepatitis B virus Immunoglobulins CHO Cells medicine.disease_cause Virus law.invention 03 medical and health sciences 0302 clinical medicine Cricetulus Hepatitis B Chronic law Cricetinae medicine Animals Humans Hepatitis B Vaccines Hepatitis B Antibodies Hepatitis B Surface Antigens Hepatology business.industry Chinese hamster ovary cell Gastroenterology Hepatitis B medicine.disease Virology Clinical trial 030220 oncology & carcinogenesis Monoclonal Recombinant DNA 030211 gastroenterology & hepatology business |
| Zdroj: | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 18(13) |
| ISSN: | 1542-7714 |
| Popis: | The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti-HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2-4. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|